Apatinib is an oral small-molecule tyrosine kinase inhibitor, which can bind to and inhibit VEGFR-2 and was approved in China for the treatment of advanced GC after failure of second-line chemotherapy [17]. This evidence concerns the gene KDR and gastric cancer.